Literature DB >> 20509054

Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.

Marc Pracht1, Catherine Le Roux, Mallorie Kerjouan, Eveline Boucher, Odile Audrain, Jean-Luc Raoul.   

Abstract

INTRODUCTION: The authors report two cases of young patients who developed clubbing and hypertrophic osteoarthropathy in one case or lung diffusion disorder in the second, after a long-term use of bevacizumab plus chemotherapy in a palliative setting of metastatic colorectal cancer. DISCUSSION: We propose that patients on long-term bevacizumab be examined for clubbing and undergo respiratory function tests and that this would be studied prospectively before beginning trials in evaluating this monoclonal antibody given for 2 years in an adjuvant setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20509054     DOI: 10.1007/s12029-010-9166-8

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  4 in total

Review 1.  Clubbing: an update on diagnosis, differential diagnosis, pathophysiology, and clinical relevance.

Authors:  Kerith E Spicknall; Matthew J Zirwas; Joseph C English
Journal:  J Am Acad Dermatol       Date:  2005-06       Impact factor: 11.527

Review 2.  Hypertrophic osteoarthropathy.

Authors:  M Martínez-Lavín
Journal:  Curr Opin Rheumatol       Date:  1997-01       Impact factor: 5.006

3.  Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing.

Authors:  Stephen Atkinson; Stephen B Fox
Journal:  J Pathol       Date:  2004-06       Impact factor: 7.996

4.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Linda H Colangelo; Samia H Lopa; Nicholas J Petrelli; Richard M Goldberg; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Seamus O'Reilly; Luis Chu; Catherine A Azar; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.